Weight Management Potential with Tirz
Packaging:
(1) 5Vials (99% Purity)+ 5x7ml Vial of Bacteriostatic Water, Boxed (Brand Packaging)
(2) 10Vials (99% Purity)+ 10x7ml Vial of Bacteriostatic Water Boxed (Brand Packaging)
Tirzepatide is a unimolecular dual agonist that activates both GIP and GLP‑1 receptors, producing combined incretin effects: enhanced glucose‑dependent insulin secretion, reduced glucagon secretion, delayed gastric emptying, and appetite suppression. These combined actions contribute to improved glycemic control and significant reductions in body weight observed in clinical research.
Key Features
- Research‑grade tirzepatide with documented purity
- Dual GIP/GLP‑1 receptor agonist activity relevant to glucose regulation and appetite suppression
- Demonstrates substantial body‑weight reduction and improved metabolic markers in clinical research settings
- Supports studies on insulin sensitivity, energy balance and obesity/metabolic disease interventions
- Supplied as lyophilized vial(s) for laboratory reconstitution and controlled use
Product Specifications
- Product name: Tirzepatide (investigational dual‑agonist peptide)
- Category: Metabolic / incretin‑class research peptide
- Format: Lyophilized powder in sterile vial (specified mg per vial to be set by supplier)
- Typical administration (research): Subcutaneous injection per protocol
- Storage (reconstituted): Refrigerate at 2–8 °C
Potential Research Applications
- Clinical and preclinical studies of type 2 diabetes and glycemic control
- Obesity and body‑composition research (weight‑loss mechanisms)
- Studies on appetite regulation, energy expenditure and metabolic biomarkers
- Combination interventions with diet, exercise or other metabolic agents
Reconstitution & Dosing Guide
Important: The following examples are for laboratory reference only. Confirm all calculations, aseptic technique and solvent compatibility with your institutional SOPs and supplier instructions before use.
Example Reconstitution
Below are straightforward conversions and common dosing examples for a 60 mg vial reconstituted with 3.0 mL bacteriostatic water (resulting concentration: 60 mg ÷ 3.0 mL = 20 mg/mL).
Concentration
- 20 mg/mL (20,000 µg/mL)
Volume-to-dose conversions (mg → mL → U‑100 insulin units)
- 0.5 mg = 0.025 mL = 2.5 units
- 1.0 mg = 0.05 mL = 5 units
- 1.5 mg = 0.075 mL = 7.5 units
- 2.0 mg = 0.10 mL = 10 units
- 2.5 mg = 0.125 mL = 12.5 units
- 5.0 mg = 0.25 mL = 25 units
- 10.0 mg = 0.50 mL = 50 units
Insulin‑syringe conversion (U‑100 reference; 100 units = 1.0 mL)
- After you define vial concentration (mg/mL), convert mg → mL → insulin units for subcutaneous delivery. Example at 5 mg/mL concentration: 1.0 mg = 0.20 mL = 20 units. Always calculate from the actual vial concentration.
Common Research Dosing Examples
- Typical mg-range single doses used in some protocols: 1 mg, 2 mg, 5 mg or 10 mg per administration (see conversions above).
- Weekly clinical-style dosing (if modelling agents dosed weekly): e.g., 2.5 mg, 5 mg, 10 mg once weekly — volumes 0.125 mL, 0.25 mL, 0.50 mL respectively.
- Fixed weekly subcutaneous dosing is typical in clinical programs (e.g., once weekly injections). Clinical study dose levels have included incremental doses up to several milligrams per week (protocol dependent).
- Typical studied dose escalation sequence in trials (example reference pattern): 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg (once weekly), with each step maintained for several weeks before escalation to improve tolerability. Exact steps and durations depend on protocol.
Administration Notes
- Subcutaneous injection is the commonly used route in clinical and research settings. Tirzepatide is typically administered once weekly in clinical trials; dosing frequency should be defined by your study protocol.
- Titration schedules are widely used to mitigate gastrointestinal side effects: start at a low weekly dose and escalate per protocol.
- Monitor blood glucose, body weight, gastrointestinal symptoms and other safety markers per protocol.
Cycle Length and Scheduling
- Clinical trials generally use continuous weekly dosing over months; dose‑finding studies escalate over several weeks to reach target maintenance doses.
- Tapering is not typically required when discontinuing after short‑term research use, but follow protocol‑specified discontinuation procedures to monitor for metabolic rebound.
Possible Observations and Adverse Events
- Expected observations: improved glycemic control, reduced appetite, and clinically significant weight loss over weeks to months when combined with lifestyle interventions.
- Common class‑related adverse events: gastrointestinal symptoms, decreased appetite, and injection‑site reactions. Monitor for hypoglycemia especially when used with other glucose‑lowering agents.
- Record and manage adverse events according to institutional safety procedures.
Handling, Stability and Storage After Reconstitution
- Reconstituted solutions: refrigerate at 2–8 °C
- Use aseptic technique and sterile supplies for reconstitution and dosing.
Frequently Asked Questions
Q: How is tirzepatide typically dosed in studies?
A: In clinical trials, tirzepatide is commonly administered once weekly with stepwise escalation (example: 2.5 mg up‑titration to higher maintenance doses) to manage tolerability.
Q: What effects are typically observed?
A: Improved glycemic markers and substantial body‑weight reductions are commonly reported in clinical research; response magnitude varies by dose and study duration.
Q: Are there safety concerns?
A: Gastrointestinal adverse effects are the most frequent; hypoglycemia risk increases when combined with other glucose‑lowering therapies. Monitor per protocol.
Legal and Regulatory Notice
By purchasing this product you confirm that you are acquiring it for lawful research purposes. It is the purchaser’s responsibility to ensure compliance with local laws, institutional policies, ethical and customs requirements. Liability for misuse is disclaimed.
For this price, there is a need to pre-order, waiting time 5 to 7 days.
